Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Louis Miller (National Institute of Allergy and Infectious Diseases) and Stephen Hoffman (Naval Medical Research Institute) review progress toward developing malaria vaccines. They argue that multiple antigens from different stages may be needed to protect the diverse populations at risk, and that an optimal vaccine would induce immunity against all stages. Vaccines for African children, in whom the major mortality occurs, must induce immunity against asexual blood stages.
Margaret A. Liu (Vice President, Vaccines Research, Chiron Corporation) reviews a wide range of approaches to vaccine design and development. Consideration is given to the particular strengths and weaknesses of protocols ranging from traditional attenuated organisms to the most innovative transgenic plants and DMA-based vaccines, and how well each is likely to meet our future vaccine needs.